White Plains, United States
Iantrek, founded in 2019, is leveraging advancements in micro-interventional eye surgery with its next-generation MIGS (Minimally Invasive Glaucoma Surgery) solutions. With its motto, "What’s next in micro-interventional eye surgery," the company is aiming to revolutionize treatment modalities in the Health Care and Health and Wellness sectors.
Based in the United States, Iantrek recently secured a $23.00M Series B investment on August 30, 2022, a testament to its potential and the confidence it has garnered from notable investment firms. The surge of interest from prominent investors such as Sectoral Asset Management and Visionary Ventures underscores the promise Iantrek holds in driving innovative solutions for eye health.
For investors, Iantrek represents a promising opportunity in an evolving market with significant growth potential, addressing critical needs in ophthalmic surgery with a focus on patient outcomes and technological advancement.
